Nav: Home

First-of-its-kind technology lights up lung cancer cells, helps improve patient outcomes

January 27, 2020

NEW ORLEANS, Louisiana (January 27, 2020) -- A groundbreaking tumor-highlighting technology--OTL38--enhances the visualization of lung cancer tissue, providing surgeons with a significantly better chance of finding and removing more cancer than previously possible, according to a scientific presentation at the 56th Annual Meeting of The Society of Thoracic Surgeons.

"Lung cancer is the most common and lethal cancer worldwide," said Inderpal (Netu) S. Sarkaria, MD, from the University of Pittsburgh Medical Center in Pennsylvania. "Technologies to improve the care of these patients are needed. Near-infrared imaging with OTL38 during surgery for lung cancer is one such promising technology with the potential to significantly improve the completeness and quality of the operation, therefore improving patient outcomes."

Dr. Sarkaria and colleagues at six institutions (University of Pittsburgh, University of Pennsylvania, Harvard University, Cleveland Clinic, Leiden University, and MD Anderson) participated in a phase 2 clinical trial, identifying 92 patients who had lung lesions and were to undergo pulmonary resection for non-small cell lung cancer (NSCLC). Before their operations, each patient received a measured intravenous dose of OTL38, composed of near-infrared dye and a targeting molecule. The molecule attaches to folic-acid-based receptors on cancer cells and can be illuminated during surgery using a special surgical endoscope. This helps identify small, hard-to-detect cancer lesions that might otherwise have been missed and should be surgically removed.

The researchers made assessments in three phases: "Lung Inspection," "Tumor Resection," and "Specimen Check." During the inspection phase, the molecular imaging identified 10 additional cancers--all missed when using visual examination and manual touch--in seven patients (8%). In the resection phase, researchers determined that OTL38 enabled localization of lesions that were not found in 11 patients (12%). After surgeons found that all margins were visually adequate or clear in the specimen check, the resected specimens were further assessed using the molecular imaging. Inadequate margins (microscopic residual tumor left at the edges) were uncovered in eight patients (9%). Overall, researchers determined that the OTL38 molecular imaging helped improve outcomes for 1-in-4 patients (26%).

"OTL38 is the first technique that is specific to imaging adenocarcinomas of the lung, which is one of the most common types of invasive lung cancer, making it unique and clinically useful in this respect," said Dr. Sarkaria. "Localization of tumors, identification of occult tumors, and immediate tumor margin assessment during surgery for adenocarcinomas of the lung were significantly improved with the use of this technology."

Surgery remains the best potentially curative treatment for early stage NSCLC. However, research has shown that 30% to 55% of patients with NSCLC develop recurrence, which often is caused by microscopic clusters of cancer cells that were undetected by standard staging methods. This suggests that complete removal needs to be ensured both macroscopically and microscopically during surgery.

"Near-infrared imaging with OTL38 may be a powerful tool to help surgeons significantly improve the quality of lung cancer surgery by more clearly identifying tumors and allowing the surgeon to better see and completely remove them--one of the most vital components in the overall care of patients with this disease," said Dr. Sarkaria.

Surgeons traditionally use X-rays, magnetic resonance imaging, computed tomography (CT) scans, positron emission tomography, and/or ultrasound to determine the size and location of tumors before surgery. However, these imaging modalities are rarely, if ever, used during surgery.

OTL38 is believed to be the first targeted fluorescent marker to provide this type of benefit for lung cancer. The OTL38 technology is different in its ability to detect cancerous tissue not previously identified on preoperative scans and do so in real-time, while the surgeon is operating. This is crucial in ensuring that surgeons adequately detect and remove cancer cells that may not be visible to the naked eye or located through touch. The complete removal of diseased tissue during surgery helps to avoid additional surgeries and cancer relapse, as well as increase patients' overall chances of survival.

"Use of advanced near-infrared imaging techniques such as OTL38 may provide surgeons with powerful tools to improve the quality of lung cancer operations by better identifying small, hard-to-find tumors, finding previously undetected cancers at the time of surgery, and better assessing if the entire tumor has been removed," said Dr. Sarkaria.

In addition, with the implementation of lung screening and the increased use of CT scans in general, cardiothoracic surgeons are seeing more patients with small or undefined nodules, so the timing of the availability of technology such as OTL38 is just right, according to Linda W. Martin, MD, MPH, of the University of Virginia in Charlottesville, who was not directly involved with this research.

"In many circumstances, a preoperative biopsy is not practical or feasible, and we are faced with the need for intraoperative identification of these nodules," said Dr. Martin. "This research describes an exciting new approach to localize nodules that are difficult to find without a separate procedure. More importantly, the study showed that because of this technology, additional nodules that were in fact separate cancers were found, and useful information about margin status also resulted."

Dr. Martin described another significant advantage that the OTL38 technology offers--the ability to better identify small nodules. This may allow surgeons to more often utilize minimally invasive operative approaches in some patients who otherwise would have been required to undergo a thoracotomy in order to find these nodules.

The completion of the OTL38 Phase 2 trial in lung cancer is a major milestone, advancing the technology closer to Food and Drug Administration approval and commercialization. Phase 3 trials currently are under way.
-end-
The other authors of the study were SP Gangadharan, DC Rice, SC Murthy, J Braun, JC Kucharczuk, J Predina, and S Singhal.

On Target Laboratories, Inc. is a privately held biotechnology company that is developing tumor-targeted fluorescent dyes such as OTL38.

Find comprehensive medical information presented for patients by leading experts in cardiothoracic surgery on the STS Patient Website (ctsurgerypatients.org). For more information, contact Senior Media Relations Manager Jennifer Bagley at 312-202-5865 or jbagley@sts.org.

Founded in 1964, The Society of Thoracic Surgeons is a not-for-profit organization representing more than 7,500 cardiothoracic surgeons, researchers, and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society's mission is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy.

The Society of Thoracic Surgeons

Related Lung Cancer Articles:

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.
Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
More Lung Cancer News and Lung Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.